The Chemrar group of companies plans to invest 1 billion rubles in the development of a new complex for the production of pharmaceutical substances in Khimki, near Moscow. This investment will also include the establishment of a workshop dedicated to the development of semifinished products, as well as warehouse facilities. This information was shared by the Main Directorate of State Construction Supervision of the Moscow Region.
The upcoming enterprise is set to commence the production of pharmaceutical substances sourced from the company’s existing portfolio, particularly targeting HIV infection and anxiety disorders, including those that emerged post-COVID-19. The press service of the department highlighted that “the new production line from AFS-Technology will amplify Chemrar‘s manufacturing capacity by over fivefold.”
The new complex will be situated within the existing Chemrar high-tech center. Construction is set to be fully completed by the end of 2024, with production scheduled to commence in the first or second quarter of 2025. This ambitious project is backed by the Industrial Development Fund, the Ministry of Industry and Trade of the Russian Federation, and the Government of the Moscow Region. Previously, the Moscow Region Ministry of Investment, Industry, and Science indicated that the complex was expected to launch in the fourth quarter of 2026.
